CADTH launches call for patient and clinician input on masitinib

October 6, 2022 – The Canadian Agency for Drugs and Technology in Health (CADTH) has posted a call for patient and clinician input on masitinib. ALS Canada will be preparing a submission reflecting the perspectives, experiences, and expectations of the ALS community.  

Preparing a patient input submission helps ensure that issues of importance to the ALS community are considered by decision-makers at CADTH, who ultimately recommend whether public drug plans should cover the drug if it is approved by Health Canada.  

At this time, Health Canada has not yet finished its review of masitinib, so a decision about its approval is still to come. You can learn more about how drugs become accessible in Canada by visiting our blog post on this topic.